CAS 1216941-48-8

Paritaprevir

Description:

Paritaprevir is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It is classified as a protease inhibitor, specifically targeting the NS3/4A protease enzyme, which is crucial for the viral replication process. Paritaprevir is often used in combination with other antiviral agents to enhance its efficacy and reduce the likelihood of resistance. The compound is characterized by its specific molecular structure, which includes a series of functional groups that contribute to its biological activity. It is typically administered orally and is known for its relatively favorable pharmacokinetic profile, including good absorption and metabolism. Paritaprevir is part of combination therapies, such as those including ritonavir, to boost its effectiveness and prolong its action. As with many medications, potential side effects may include fatigue, nausea, and liver enzyme elevations, necessitating monitoring during treatment. Overall, Paritaprevir represents a significant advancement in the management of chronic hepatitis C infections.

Formula: C₄₀H₄₃N₇O₇S

InChI: InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1

InChI key: InChIKey=UAUIUKWPKRJZJV-QPLHLKROSA-N

SMILES: C(NS(=O)(=O)C1CC1)(=O)[C@]23[C@@](C2)(/C=C\CCCCC[C@H](NC(=O)C=4C=NC(C)=CN4)C(=O)N5[C@](C(=O)N3)(C[C@@H](OC6=C7C(=C8C(=N6)C=CC=C8)C=CC=C7)C5)[H])[H]

Synonyms:

• (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
• Abt 450
• Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-
• Paritaprevir
• ABT450

Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-

CAS: 1216941-48-8

Formula: C₄₀H₄₃N₇O₇S

Purity: 98%

Color and Shape: Solid

Molecular weight: 765.8771

Ref: IN-DA0015L7

Paritaprevir

CAS: 1216941-48-8

Formula: C₄₀H₄₃N₇O₇S

Color and Shape: White To Off-White Solid

Molecular weight: 765.89

Ref: 4Z-P-232001

Paritaprevir

CAS: 1216941-48-8

Paritaprevir

Purity: ≥98%

Molecular weight: 765.88g/mol

Ref: 54-BUP10483

Paritaprevir

CAS: 1216941-48-8

Paritaprevir (ABT450) 是一种非结构蛋白 3/4A 蛋白酶抑制剂，对 HCV 1a 和 HCV 1b 的 EC50 值分别为 1 和 0.21 nM。它也是SARS-CoV 3CLpro 的抑制剂，IC50为 1.31 μM。

Formula: C₄₀H₄₃N₇O₇S

Purity: 99.72%

Color and Shape: Solid

Molecular weight: 765.88

Ref: TM-T22394

Paritaprevir-d5

CAS: 1216941-48-8

Formula: C₄₀H₃₈N₇O₇SD₅

Molecular weight: 770.93

Ref: 4Z-P-232002

Paritaprevir

Controlled Product

CAS: 1216941-48-8

Applications Paritaprevir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
References Feld, J.J., et al.: New Eng. J. Med., 370, 1594 (2014); Lawitz, E., et al.: J. Hepatol., 57, 24 (2012); Afdhal, N., et al.: New England J. Med., 370, 1889 (2014)

Formula: C₄₀H₄₃N₇O₇S

Color and Shape: Neat

Molecular weight: 765.877

Ref: TR-P195305

Paritaprevir

CAS: 1216941-48-8

Paritaprevir is an antiviral medication, which is derived from chemical synthesis with its action targeting the hepatitis C virus (HCV). It operates primarily as a protease inhibitor, specifically targeting the NS3/4A protease, an essential enzyme for HCV replication. By inhibiting this protease, Paritaprevir effectively disrupts the viral life cycle, preventing the virus from maturing and proliferating within the host cells.

Purity: Min. 95%

Ref: 3D-AP178043